Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic … Read more
Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.29 Billion CNY
Based on the latest financial reports, Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) has total liabilities worth CN¥1.29 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Chongqing Genrix Biopharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chongqing Genrix Biopharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Chongqing Genrix Biopharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grape King Bio Ltd
TW:1707
|
Taiwan | NT$2.85 Billion |
|
PT Sarana Menara
JK:TOWR
|
Indonesia | Rp57.73 Trillion |
|
Logility Supply Chain Solutions, Inc.
NASDAQ:LGTY
|
USA | $54.87 Million |
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
China | CN¥1.08 Billion |
|
Fuller Smith & Turner P.L.C
PINK:FTUAF
|
USA | $291.30 Million |
|
China Motor Corp
TW:2204
|
Taiwan | NT$13.42 Billion |
|
Alarko Holding AS
IS:ALARK
|
Turkey | TL43.30 Billion |
|
Hanjaya Mandala Sampoerna Tbk PT
JK:HMSP
|
Indonesia | Rp21.62 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down Chongqing Genrix Biopharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Genrix Biopharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Genrix Biopharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Chongqing Genrix Biopharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.02 Billion | +25.83% |
| 2023-12-31 | CN¥810.36 Million | -13.15% |
| 2022-12-31 | CN¥933.03 Million | +35.06% |
| 2021-12-31 | CN¥690.84 Million | -- |